Standard BioTools (NASDAQ:LAB – Get Free Report) is projected to issue its Q2 2025 quarterly earnings data after the market closes on Monday, August 11th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $39.83 million for the quarter.
Standard BioTools Stock Performance
NASDAQ LAB opened at $1.30 on Monday. Standard BioTools has a twelve month low of $0.92 and a twelve month high of $2.32. The stock has a market cap of $493.77 million, a price-to-earnings ratio of -3.71 and a beta of 1.32. The firm’s 50 day moving average price is $1.21 and its two-hundred day moving average price is $1.22.
Hedge Funds Weigh In On Standard BioTools
An institutional investor recently raised its position in Standard BioTools stock. AQR Capital Management LLC grew its stake in shares of Standard BioTools Inc. (NASDAQ:LAB – Free Report) by 862.2% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 482,912 shares of the company’s stock after acquiring an additional 432,725 shares during the period. AQR Capital Management LLC owned 0.13% of Standard BioTools worth $522,000 as of its most recent SEC filing. Institutional investors and hedge funds own 53.74% of the company’s stock.
Analysts Set New Price Targets
Check Out Our Latest Report on Standard BioTools
Standard BioTools Company Profile
Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
See Also
- Five stocks we like better than Standard BioTools
- What is the Shanghai Stock Exchange Composite Index?
- Why Teradyne’s 19% Rally Is Just Getting Started
- How to Short a Stock in 5 Easy Steps
- Buy the Dip on 3 Overlooked Names With Major Potential
- 3 Defense Stocks Set to Benefit From Increased Military Spending
- Bitcoin and Dividends: A Winning Combo in These 3 ETFs
Receive News & Ratings for Standard BioTools Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Standard BioTools and related companies with MarketBeat.com's FREE daily email newsletter.
